Torsemide Comparison With Furosemide for Management of Heart Failure - TRANSFORM-HF
Contribution To Literature:
The TRANSFORM-HF trial failed to show that torsemide was superior to furosemide in improving survival among patients treated for decompensated heart failure.
The goal of the trial was to evaluate furosemide compared with torsemide after hospitalization for decompensated heart failure.
Patients hospitalized with decompensated heart failure were randomized to furosemide (n = 1,428) vs. torsemide (n = 1,431) after discharge.
- Total number of enrollees: 2,859
- Median duration of follow-up: 17.4 months
- Mean patient age: 64 years
- Percentage female: 37%
- Patients hospitalized with decompensated heart failure regardless of ejection fraction
The primary outcome, all-cause mortality, occurred in 26.2% of the furosemide group vs. 26.1% of the torsemide group (p = 0.76).
- All-cause mortality or hospitalization: 49.3% of the furosemide group vs. 47.3% of the torsemide group (p = 0.11)
Among patients admitted with decompensated heart failure, post-discharge management with torsemide was not superior to furosemide. All-cause mortality was similar between treatment groups. Either furosemide or torsemide are acceptable options for diuresis among patients with heart failure.
Highlighted text has been updated as of February 27, 2023.
Mentz RJ, Anstrom KJ, Eisenstein EL, et al. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA 2023;329:214-23.
Editorial: Kittleson MM. TRANSFORM-HF—Can We Close the Loop on Diuretics in Heart Failure? JAMA 2023;329:211-3.
Presented by Dr. Robert J. Mentz at the American Heart Association Scientific Sessions, Chicago, IL, November 5, 2022.
Clinical Topics: Heart Failure and Cardiomyopathies, Statins, Acute Heart Failure
Keywords: AHA Annual Scientific Sessions, AHA22, Diuresis, Furosemide, Heart Failure, Patient Discharge, Stroke Volume, Torsemide
< Back to Listings